This supports the notion that WT1 downregulation in AML might reflect the accumulation of mutations characteristic of CHIP and thereafter MR-AML, which often signify a more slow-growing but biologically complex form of the disease. The gene discussed is STUB1; the disease is acute myeloid leukemia.